by David Wallace
What are some of the latest combination drug treatments in development for MPN? Find out the latest on combination add-on strategies to JAK inhibitors and other new agents. Two combination therapies for Myelofibrosis look promising as they move into phase 3 clinical trials. They include adding CPI-0610 (a bromodomain, BET, inhibitor) and navitoclax (a BC-XL inhibitor) to ruxolitinib. What other new agents look most promising?
Learn more as Dr. Naveen Pemmaraju, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX interviews with David Wallace, PV Reporter founder and polycythemia vera patient reporting virtually from ASH 2020.
